丸美生物
(603983)
| 流通市值：137.54亿 | | | 总市值：137.54亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,663,082,248.33 | 881,288,902.19 | 3,459,318,084 | 2,450,380,539.41 |
| 营业收入 | 1,663,082,248.33 | 881,288,902.19 | 3,459,318,084 | 2,450,380,539.41 |
| 二、营业总成本 | 1,541,827,838.79 | 761,891,108.23 | 3,214,916,856.76 | 2,206,220,208.73 |
| 营业成本 | 438,275,978.16 | 230,723,580.97 | 889,519,268.27 | 614,706,979.79 |
| 税金及附加 | 15,253,656.39 | 8,429,348.73 | 40,468,775.32 | 28,878,373.64 |
| 销售费用 | 975,340,186.42 | 474,332,256.37 | 2,056,503,826.51 | 1,414,567,358.33 |
| 管理费用 | 72,989,522.88 | 31,601,889.34 | 160,992,386.17 | 101,172,990.99 |
| 研发费用 | 44,580,380.56 | 20,554,031.79 | 85,371,565.84 | 62,788,807.55 |
| 财务费用 | -4,611,885.62 | -3,749,998.97 | -17,938,965.35 | -15,894,301.57 |
| 其中:利息费用 | 2,246,940.62 | 2,683,189.39 | 3,282,855.41 | 2,689,869.53 |
| 其中:利息收入 | 6,873,962.28 | 6,616,049.33 | 21,696,773.74 | 18,928,874.75 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -4,500,110.53 | 129,452.06 | 432,554.85 | 22,698,859.7 |
| 加:投资收益 | 63,967,148.09 | 1,171,355.19 | 27,553,438.99 | 16,823,669.04 |
| 资产处置收益 | - | - | 377,398.06 | 377,398.06 |
| 资产减值损失(新) | -2,110,173.95 | -1,062,351.02 | -3,287,597.39 | -1,715,369.91 |
| 信用减值损失(新) | 171,339.89 | 618,339.52 | -312,116.8 | 319,316.89 |
| 其他收益 | 4,514,729.11 | 2,621,870.99 | 27,446,152.38 | 16,412,852.63 |
| 四、营业利润 | 183,297,342.15 | 122,876,460.7 | 296,611,057.33 | 299,077,057.09 |
| 加:营业外收入 | 532,516.76 | 477,060.01 | 688,747.35 | 570,962.23 |
| 减:营业外支出 | 992,065.73 | 126,774.09 | 1,568,360.1 | 1,126,541.95 |
| 五、利润总额 | 182,837,793.18 | 123,226,746.62 | 295,731,444.58 | 298,521,477.37 |
| 减:所得税费用 | 25,882,371.05 | 22,228,994.42 | 48,988,618.75 | 51,872,160.73 |
| 六、净利润 | 156,955,422.13 | 100,997,752.2 | 246,742,825.83 | 246,649,316.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 156,955,422.13 | 100,997,752.2 | 246,742,825.83 | 246,649,316.64 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 155,470,787.09 | 101,019,964.38 | 247,239,140.99 | 243,892,254.22 |
| 少数股东损益 | 1,484,635.04 | -22,212.18 | -496,315.16 | 2,757,062.42 |
| 扣除非经常损益后的净利润 | 112,701,590.82 | 99,878,281.38 | 231,225,157.4 | 214,069,755.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.39 | 0.25 | 0.62 | 0.61 |
| (二)稀释每股收益 | 0.39 | 0.25 | 0.62 | 0.61 |
| 八、其他综合收益 | -265,302.03 | -24,389.15 | -22,246.12 | -73,087.1 |
| 归属于母公司股东的其他综合收益 | -265,302.03 | -24,389.15 | -22,246.12 | -73,087.1 |
| 九、综合收益总额 | 156,690,120.1 | 100,973,363.05 | 246,720,579.71 | 246,576,229.54 |
| 归属于母公司股东的综合收益总额 | 155,205,485.06 | 100,995,575.23 | 247,216,894.87 | 243,819,167.12 |
| 归属于少数股东的综合收益总额 | 1,484,635.04 | -22,212.18 | -496,315.16 | 2,757,062.42 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-04-01 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |